Results 31 to 40 of about 8,597,475 (170)

Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden [PDF]

Ophthalmology and Therapy
Introduction This study aimed to evaluate functional, anatomical, and safety outcomes after switching from aflibercept 2 mg to aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) requiring short re-treatment intervals in
Christoph Spartalis, Marlies Ullrich, Silvia Winkler, Christoph Leisser, Manuel Ruiss, Caroline Pilwachs, Oliver Findl   +6 more
doaj   +2 more sources

Short-term intraocular pressure changes following intravitreal aflibercept 8 mg versus 2 mg in diabetic macular edema: a prospective observational study [PDF]

Scientific Reports
This prospective observational study evaluated short-term intraocular pressure (IOP) changes and safety following intravitreal injection of aflibercept 8 mg versus 2 mg in diabetic macular edema (DME).
Ken Hoshiyama, Takao Hirano, Erika Sekiya, Shingo Kajiwara, Shuji Mukawa, Yoshiaki Chiku, Marie Nakamura, Noriko Yoshida, Toshinori Murata   +8 more
doaj   +2 more sources

Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis [PDF]

Ophthalmology and Therapy
Introduction Aflibercept 8 mg administered in extended dosing intervals has shown non-inferior visual gains and comparable safety profile to aflibercept 2 mg in the PULSAR pivotal randomized clinical trial and has the potential to reduce the treatment ...
Piotr Wojciechowski, Marlena Wdowiak, Malgorzata Panek, Izabella Lunk, Joao Carrasco, Xin Zhang, Olivia Wu, Jean-François Korobelnik, Paolo Lanzetta   +8 more
doaj   +2 more sources

Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification

Ophthalmology and Therapy
Introduction To evaluate the early outcomes of aflibercept 8 mg (afl8) treatment in patients with neovascular age-related macular degeneration (nAMD) previously treated with aflibercept 2 mg (afl2).
Nicolò Bartolomeo, Konstantinos Kitsos Kalyvianakis, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, Daniela Gallo Castro, Baptiste Crozat, Mamadou Pathé Barry, Aude Ambresin   +7 more
doaj   +4 more sources

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases [PDF]

International Medical Case Reports Journal
Ikumi Kashiwagi, Ryota Nonaka, Shotaro Sasaki, Takuto Yamamoto, Kanako Yasuda, Masahiko Shimura Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, JapanCorrespondence: Masahiko Shimura, Department of ...
Kashiwagi I, Nonaka R, Sasaki S, Yamamoto T, Yasuda K, Shimura M   +5 more
doaj   +1 more source

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +2 more sources

Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom [PDF]

Life
(1) Aim: To evaluate early real-world outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD) in the United Kingdom. (2) Methods: This retrospective, observational study included 59 eyes from 50 patients
Muiz Musadiq, Mohammed Musadiq, Fozia Latif, Benjamin Ng, Matthew Azzopardi, Noa Gilead, Andrew Needham, Yu Jeat Chong   +7 more
doaj   +2 more sources

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products

CPT: Pharmacometrics & Systems Pharmacology
Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in ...
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Torsten Zimmermann, Zhongqing Will He, John D. Davis, A. Thomas DiCioccio, Lutz O. Harnisch   +10 more
doaj   +2 more sources

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials

Ophthalmology and Therapy
Introduction Reducing intravitreal injection frequency while maintaining efficacy is a critical goal in alleviating the burden associated with anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema (DME) or ...
Scott M. Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping, Keith Chan, Theodore Leng, Nimesh Patel   +8 more
doaj   +2 more sources

Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema

AJO International
Objective: To evaluate and compare the effectiveness and treatment burden of faricimab and aflibercept 8 mg in treatment-naive patients with diabetic macular edema (DME) using a pro re nata (PRN) protocol.
Carlo Maccauro, Yanny Jimenez Perez, Piergiorgio Neri, Ibraheem El Ghrably, Haytham I Salti, Francesco Pichi   +5 more
doaj   +2 more sources